ALLO Allogene Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALLO

Price (delayed)

$3

Market cap

$512.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.82

Enterprise value

$451.23M

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by ...

Highlights
Allogene Therapeutics's debt has plunged by 100% YoY
ALLO's quick ratio has surged by 58% year-on-year and by 3.3% since the previous quarter
The gross profit is down by 48% year-on-year and by 32% since the previous quarter
ALLO's revenue is down by 48% year-on-year and by 32% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.allogene.com
Peers: OMGA ONCT

Key stats

What are the main financial stats of ALLO
Market
Shares outstanding
170.85M
Market cap
$512.56M
Enterprise value
$451.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.1
Price to sales (P/S)
7,805.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6,941.99
Earnings
Revenue
$65,000
EBIT
-$293.56M
EBITDA
-$279.31M
Free cash flow
-$227.48M
Per share
EPS
-$1.82
Free cash flow per share
-$1.35
Book value per share
$2.73
Revenue per share
$0
TBVPS
$3.47
Balance sheet
Total assets
$586.35M
Total liabilities
$124.98M
Debt
$0
Equity
$461.37M
Working capital
$364.47M
Liquidity
Debt to equity
0
Current ratio
12.8
Quick ratio
12.79
Net debt/EBITDA
0.22
Margins
EBITDA margin
-429,713.8%
Gross margin
100%
Net margin
-451,632.3%
Operating margin
-458,724.6%
Efficiency
Return on assets
-43.3%
Return on equity
-53.9%
Return on invested capital
-50.3%
Return on capital employed
-52.9%
Return on sales
-451,632.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALLO stock price

How has the Allogene Therapeutics stock price performed over time
Intraday
3.09%
1 week
6.01%
1 month
28.21%
1 year
-40.71%
YTD
-6.54%
QTD
28.76%

Financial performance

How have Allogene Therapeutics's revenue and profit performed over time
Revenue
$65,000
Gross profit
$65,000
Operating income
-$298.17M
Net income
-$293.56M
Gross margin
100%
Net margin
-451,632.3%
The operating margin has dropped by 62% year-on-year and by 33% since the previous quarter
Allogene Therapeutics's net margin has plunged by 57% YoY and by 31% from the previous quarter
The gross profit is down by 48% year-on-year and by 32% since the previous quarter
ALLO's revenue is down by 48% year-on-year and by 32% since the previous quarter

Growth

What is Allogene Therapeutics's growth rate over time

Valuation

What is Allogene Therapeutics stock price valuation
P/E
N/A
P/B
1.1
P/S
7,805.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6,941.99
The EPS has grown by 27% YoY and by 13% from the previous quarter
ALLO's price to book (P/B) is 63% less than its 5-year quarterly average of 2.9 and 11% less than its last 4 quarters average of 1.2
Allogene Therapeutics's equity has decreased by 22% YoY and by 10% QoQ
ALLO's revenue is down by 48% year-on-year and by 32% since the previous quarter
The stock's price to sales (P/S) is 7% less than its last 4 quarters average of 8156.4

Efficiency

How efficient is Allogene Therapeutics business performance
The ROS has plunged by 57% YoY and by 31% from the previous quarter
ALLO's return on invested capital is down by 8% year-on-year but it is up by 3.8% since the previous quarter
The return on assets has increased by 5% since the previous quarter but it has declined by 2.1% year-on-year
The return on equity has increased by 4.9% since the previous quarter but it has declined by 4.7% year-on-year

Dividends

What is ALLO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALLO.

Financial health

How did Allogene Therapeutics financials performed over time
ALLO's current ratio has soared by 58% YoY and by 3.4% from the previous quarter
ALLO's quick ratio has surged by 58% year-on-year and by 3.3% since the previous quarter
Allogene Therapeutics's debt is 100% less than its equity
The company's debt to equity has shrunk by 100% YoY
Allogene Therapeutics's debt has plunged by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.